Focus: Oruka Therapeutics is a clinical-stage biotech company focused on developing biologic therapeutics for skin diseases, particularly dermatology indications. The company is currently advancing programs in early-to-mid clinical development with a concentrated pipeline.
Profile data last refreshed 10h ago · AI intelligence enriched 3w ago
Stable — net -2 jobs in 30d
3 added, 5 removed. Backfill posture.
Oruka is a lean, early-stage dermatology biotech with meaningful clinical activity and strategic hiring in data and operations—suitable for risk-tolerant professionals seeking formative biotech experience, but financial opacity demands due diligence on funding runway.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Oruka Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Oruka Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Oruka Therapeutics, Inc. - Common Stock (ORKA) Stock Price, News, Quote & History - FinancialContent
Oruka Therapeutics, Inc. - Common Stock (ORKA) Stock Price, News, Quote & History FinancialContent
Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results - Yahoo Finance
Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results Yahoo Finance
Oruka Therapeutics, Inc. (ORKA) stock price, news, quote and history - Yahoo Finance Singapore
Oruka Therapeutics, Inc. (ORKA) stock price, news, quote and history Yahoo Finance Singapore
Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift” - TIKR.com
Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift” TIKR.com
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis - Slideshow (NASDAQ:ORKA) 2026-10-26 - Seeking Alpha
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis - Slideshow (NASDAQ:ORKA) 2026-10-26 Seeking Alpha
Oruka Therapeutics Stock Soars - Here's Why - Oruka Therapeutics (NASDAQ:ORKA) - Benzinga
Oruka Therapeutics Stock Soars - Here's Why - Oruka Therapeutics (NASDAQ:ORKA) Benzinga
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo